Search Results - "Rink, Lori"

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study by von Mehren, Margaret, George, Suzanne, Heinrich, Michael C, Schuetze, Scott M, Yap, Jeffrey T, Yu, Jain Q, Abbott, Amanda, Litwin, Samuel, Crowley, John, Belinsky, Martin, Janeway, Katherine A, Hornick, Jason L, Flieder, Douglas B, Chugh, Rashmi, Rink, Lori, Van den Abbeele, Annick D

“…Most gastrointestinal stromal tumors (GIST) have activating mutations of , or uncommonly . Fifteen percent of adult and 85% of pediatric GISTs are wild type…”
Get full text

Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion by Atay, Safinur, Banskota, Samagya, Crow, Jennifer, Sethi, Geetika, Rink, Lori, Godwin, Andrew K.

“…During tumor development, constant interplay occurs between tumor cells and surrounding stromal cells. We report evidence that gastrointestinal stromal tumor…”
Get full text

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors by Tarn, Chi, Rink, Lori, Merkel, Erin, Flieder, Douglas, Pathak, Harsh, Koumbi, Daphne, Testa, Joseph R, Eisenberg, Burton, von Mehren, Margaret, Godwin, Andrew K

“…A subset of gastrointestinal stromal tumors (GISTs) lack gain-of-function mutations in c-KIT and PDGFRα. These so-called wild-type (WT) GISTs tend to be less…”
Get full text

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST by Belinsky, Martin G, Cai, Kathy Q, Zhou, Yan, Luo, Biao, Pei, Jianming, Rink, Lori, von Mehren, Margaret

“…Most gastrointestinal stromal tumors (GISTs) harbor mutually exclusive gain of function mutations in the receptor tyrosine kinase (RTK) KIT (70-80%) or in the…”
Get full text

Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data by OCHS, Michael F, RINK, Lori, TARN, Chi, MBURU, Sarah, TAGUCHI, Takahiro, EISENBERG, Burton, GODWIN, Andrew K

“…Cell signaling plays a central role in the etiology of cancer. Numerous therapeutics in use or under development target signaling proteins; however, off-target…”
Get full text

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor by Rink, Lori, Ochs, Michael F, Zhou, Yan, von Mehren, Margaret, Godwin, Andrew K

“…Although imatinib mesylate (IM) has transformed the treatment of gastrointestinal stromal tumors (GIST), many patients experience primary/secondary drug…”
Get full text

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor by Rink, Lori, Skorobogatko, Yuliya, Kossenkov, Andrew V, Belinsky, Martin G, Pajak, Thomas, Heinrich, Michael C, Blanke, Charles D, von Mehren, Margaret, Ochs, Michael F, Eisenberg, Burton, Godwin, Andrew K

“…Despite initial efficacy of imatinib mesylate in most gastrointestinal stromal tumor (GIST) patients, many experience primary/secondary drug resistance…”
Get full text

Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment by Ye, Shuai, Sharipova, Dinara, Kozinova, Marya, Klug, Lilli, D'Souza, Jimson, Belinsky, Martin G, Johnson, Katherine J, Einarson, Margret B, Devarajan, Karthik, Zhou, Yan, Litwin, Samuel, Heinrich, Michael C, DeMatteo, Ronald, von Mehren, Margaret, Duncan, James S, Rink, Lori

“…Management of gastrointestinal stromal tumors (GISTs) has been revolutionized by the identification of activating mutations in KIT and PDGFRA and clinical…”
Get full text

Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma by Hindin, David, MD, Rink, Lori, PhD, Huang, Min, MD, PhD, Chun, Yun Shin, MD, FACS

Get full text

ATR-Chk1 Axis Protects BCR/ABL Leukemia Cells from the Lethal Effect of DNA Double-Strand Breaks by Nieborowska-Skorska, Margaret, Stoklosa, Tomasz, Datta, Mandrita, Czechowska, Agnieszka, Rink, Lori, Slupianek, Artur, Koptyra, Mateusz, Seferynska, Ilona, Krszyna, Konrad, Blasiak, Janusz, Skorski, Tomasz

“…BCR/ABL-positive leukemia cells accumulated more replication-dependent DNA double-strand breaks (DSBs) than normal counterparts after treatment with cisplatin…”
Get full text

The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors by Belinsky, Martin G., Rink, Lori, Cai, Kathy Q., Ochs, Michael F., Eisenberg, Burton, Huang, Min, von Mehren, Margaret, Godwin, Andrew K.

“…The majority of gastrointestinal stromal tumors (GISTs) are characterized by oncogenic gain-of-function mutations in the receptor tyrosine kinase (RTK) c-KIT…”
Get full text

SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) by Movva, Sujana, Matloob, Sahar, Handorf, Elizabeth A, Choy, Edwin, Merriam, Priscilla, Flieder, Douglas B, Cai, Kathy Q, Zhou, Yan, Tetzlaff, Eric D, Pagan, Cheyenne, Barker, Emma, Veggeberg, Rosanna, Zumpano, Delia, Rink, Lori, von Mehren, Margaret, George, Suzanne

“…Dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS) are two common subtypes of soft-tissue sarcoma, a rare group of diseases for which new treatments…”
Get full text

Creation and characterization of a novel human PDGFRA D842V-mutant GIST cell line by Klug, Lillian Rose, Abalakov, Gleb, Griffith, Diana, Town, Ajia, McKinley, Arin, Grunewald, Susanne, Bauer, Sebastian, Rink, Lori, Heinrich, Michael C.

“…Abstract only e22512 Background: Activating PDGFRA mutations are seen in about 10% of gastrointestinal stromal tumors (GIST). Of these, the majority are one…”
Get full text

Abstract A02: Succinate dehydrogenase deficiency in a PDGFRA mutated gastrointestinal stromal tumor by Belinsky, Martin G., Rink, Lori, Cai, Kathy K., Luo, Biao, Zhou, Yan, Mehren, Margaret von

“…Abstract Most gastrointestinal stromal tumors harbor mutually exclusive gain-of-function mutations in the receptor tyrosine kinase (RTK) KIT (70-80%) or in the…”
Get full text

Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS) by von Mehren, Margaret, Movva, Sujana, Handorf, Elizabeth A., Merriam, Priscilla, Morgan, Jeffrey A., Choy, Edwin, Tetzlaff, Eric Daniel, Barker, Emma, Harley, Allisa Cherae, King, April, Matloob, Sahar, Jerome, Erika, Rink, Lori, George, Suzanne

“…Abstract only 11515 Background: Dedifferentiated liposarcoma (DDL) is characterized by ring chromosomes of chromosone12, which includes amplification of MDM2…”
Get full text

Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor by Zook, Phillip, Pathak, Harsh B, Belinsky, Martin G, Gersz, Lawrence, Devarajan, Karthik, Zhou, Yan, Godwin, Andrew K, von Mehren, Margaret, Rink, Lori

“…Gastrointestinal stromal tumors (GIST) generally harbor activating mutations in the receptor tyrosine kinase KIT or in the related platelet-derived growth…”
Get full text

SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS) by Movva, Sujana, von Mehren, Margaret, Handorf, Elizabeth A., Morgan, Jeffrey A., Nathenson, Michael, Thornton, Katherine Anne, Tetzlaff, Eric Daniel, Barker, Emma, Thibodeau, Linda, Harley, Allisa Cherae, King, April, Veggeberg, Rosanna, Leshner, Juliet A., Rink, Lori, George, Suzanne

“…Abstract only 11544 Background: Inhibition of CDK4 is being studied in a variety of sarcomas, especially dedifferentiated liposarcoma (DDL) where prolonged…”
Get full text

Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors by Belinsky, Martin G., Rink, Lori, Flieder, Douglas B., Jahromi, Mona S., Schiffman, Joshua D., Godwin, Andrew K., Mehren, Margaret von

“…Approximately 15% of gastrointestinal stromal tumors (GISTs) in adults and 85% in children lack mutations in KIT and PDGFRA and are known as wild‐type GISTs…”
Get full text

Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study by Chun, Yun Shin, Huang, Min, Rink, Lori, Von Mehren, Margaret

“…The insulin-like growth factor (IGF) pathway is implicated in the pathogenesis of hepatocellular carcinoma (HCC) and may be important in nonalcoholic fatty…”
Get full text

Abstract 4808: Combinations of imatinib mesylate with AKT inhibitor (miransertib, ARQ 751) or FGFR inhibitor (derazantinib) show synergy in GIST cell lines and preclinical models by Kozinova, Marya, Joshi, Shalina, Devarajan, Karthik, Zook, Phillip, D'Souza, Jimson W., Farma, Jeffrey M., Esnaola, Nestor, Foroughi, Reza, Yu, Yi, Schwartz, Brian, Hall, Terence, Mehren, Margaret von, Rink, Lori A.

“…Abstract The majority of gastrointestinal stromal tumors (GIST) harbor oncogenic mutations in the receptor tyrosine kinase KIT or platelet-derived growth…”
Get full text